Business
Theralase Named to 2019 TSX Venture 50(TM)
Theralase Achieves Third Place in the Clean Technology and Life Sciences Category on t...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase Named to 2019 TSX Venture 50(TM)Theralase Achieves Third Place in the Clean Technology and Life Sciences Category on the 2019 TSX Venture 50 TMTORONTO, ON / ACCESSWIRE / February 28, 2019 / Theralase Technologies Inc. (\"Theralase®\" or the \"Company\") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated photo dynamic compounds and their associated drug formulations intended to safely and effectively destroy various cancers has been named third place on the 2019 TSX Venture 50TM in the Clean Technology & Life Sciences sector amongst all TSX Venture Exchange listed companies. The ranking is comprised of ten companies from each of five industry sectors, selected based on three equally weighted criteria: market capitalization growth, share price appreciation and trading volume amount. Theralase is a previous winner of the 2015 TSX Venture 50TM.Dr. Shawn Shirazi, Ph.D., Chief Executive Officer – Drug Division, Theralase stated that, \"Theralase's achievement of third place in the 2019 TSX Venture 50TM top performing companies is a strong indication of the value that the Company has delivered to shareholders last year. In 2018, Theralase successfully completed a Phase Ib Non-Muscle Invasive Bladder Cancer (\"NMIBC\") clinical study and in 2019 is focused on the commencement of a Phase II NMIBC clinical study, with a primary endpoint of efficacy. The Phase Ib clinical study recently demonstrated that even a single treatment of Theralase's Anti-Cancer Technology (\"ACT\") is able to achieve a complete response at 360 days post treatment for patients presenting with Bacillus Calmete Guérin - Unresponsive NMIBC. I want to thank all our stakeholders in the achievement of this objective, including: directors, officers, management, employees, the clinical team, the scientific team, the engineering team and of course the patients, who participated in the clinical study.\"Kipton Lade, B.Sc., M.Sc., MBA., Chief Executive Officer - Device Division, Theralase stated, \"Building on a strong foundation, Theralase has had a landmark year in 2018; however, the Company is not content to rest on its laurels. We strongly believe that Theralase's anti-pain technology and ACT have the potential to be the next gold standard in the treatment of chron...